歌礼制药：ASC50治疗银屑病美国I期临床试验完成首批受试者给药

Core Viewpoint - The company announced the completion of the first dosing of healthy subjects in a Phase I clinical trial for its orally administered small molecule IL-17 targeted inhibitor ASC50, aimed at treating psoriasis [1] Group 1 - The trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ASC50 [1] - Preclinical data suggests that ASC50 has the potential to become a best-in-class oral medication for psoriasis, administered once daily [1]